Bisphosphonates improve trabecular bone mass and normalize cortical thickness in ovariectomized, osteoblast connexin43 deficient mice

Bone

Volumn 51, Issue 4, 2012, Pages 787-794

  Watkins, Marcus P ^a   Norris, Jin Yi ^a   Grimston, Susan K ^a   Zhang, Xiaowen ^a   Phipps, Roger J ^b   Ebetino, Frank H ^c   Civitelli, Roberto ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HUSSON UNIVERSITY   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Bisphosphonate; Conditional Knockout; Gap junctions

Indexed keywords

ALENDRONIC ACID; CONNEXIN 43; RISEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE ATROPHY; BONE MASS; BONE STRENGTH; CELL COUNT; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; KNOCKOUT MOUSE; MOUSE; NONHUMAN; OSTEOCLAST; PROTEIN FUNCTION; TRABECULAR BONE; WILD TYPE;

ABSORPTIOMETRY, PHOTON; ANIMALS; BIOMECHANICS; BONE AND BONES; BONE DENSITY; CONNEXIN 43; DIPHOSPHONATES; FEMALE; MICE; MICE, TRANSGENIC; ORGAN SIZE; OSTEOBLASTS; OVARIECTOMY;

EID: 84865662860     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2012.06.018     Document Type: Article

References (37)

1. Lowenstein W.R. Junctional intercellular communication: the cell-to-cell membrane channel. Physiol Rev 1981, 61:829-913.
2. Goodenough D.A., Paul D.L. Beyond the gap: functions of unpaired connexon channels. Nat Rev Mol Cell Biol 2003, 4:285-294.
3. Plotkin L.I., Manolagas S.C., Bellido T. Transduction of cell survival signals by connexin-43 hemichannels. J Biol Chem 2002, 277:8648-8657.
4. Plotkin L.I., Aguirre J.I., Kousteni S., Manolagas S.C., Bellido T. Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. J Biol Chem 2005, 280:7317-7325.
5. Plotkin L.I., Lezcano V., Thostenson J., Weinstein R.S., Manolagas S.C., Bellido T. Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo. J Bone Miner Res 2008, 23:1712-1721.
6. Rogers M.J., Frith J.C., Luckman S.P., Coxon F.P., Benford H.L., Monkkonen J., et al. Molecular mechanisms of action of bisphosphonates. Bone 1999, 24:73S-79S.
7. Bellido T., Plotkin L.I. Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability. Bone 2011, 49:50-55.
8. Russell R.G., Watts N.B., Ebetino F.H., Rogers M.J. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008, 19:733-759.
9. Idris A.I., Rojas J., Greig I.R., Van't Hof R.J., Ralston S.H. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro. Calcif Tissue Int 2008, 82:191-201.
10. Canalis E., Mazziotti G., Giustina A., Bilezikian J.P. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 2007, 18:1319-1328.
11. Chung D.J., Castro C.H., Watkins M., Stains J.P., Chung M.Y., Szejnfeld V.L., et al. Low peak bone mass and attenuated anabolic response to parathyroid hormone in mice with an osteoblast-specific deletion of connexin43. J Cell Sci 2006, 119:4187-4198.
12. Grimston S.K., Brodt M.D., Silva M.J., Civitelli R. Attenuated response to in vivo mechanical loading in mice with conditional osteoblast ablation of the connexin43 gene (Gja1). J Bone Miner Res 2008, 23:879-886.
13. Grimston S.K., Goldberg D.B., Watkins M., Brodt M.D., Silva M.J., Civitelli R. Connexin43 deficiency reduces the sensitivity of cortical bone to the effects of muscle paralysis. J Bone Miner Res 2011, 26:2151-2160.
14. Watkins M., Grimston S.K., Norris J.Y., Guillotin B., Shaw A., Beniash E., et al. Osteoblast connexin43 modulates skeletal architecture by regulating both arms of bone remodeling. Mol Biol Cell 2011, 22:1240-1251.
15. Bivi N., Condon K.W., Allen M.R., Farlow N., Passeri G., Brun L.R., et al. Cell autonomous requirement of connexin 43 for osteocyte survival: consequences for endocortical resorption and periosteal bone formation. J Bone Miner Res 2011, 27:374-389.
16. Zhang Y., Paul E.M., Sathyendra V., Davison A., Sharkey N., Bronson S., Srinivasan S., Gross T.S., Donahue H.J. Enhanced osteoclastic resorption and responsiveness to mechanical load in gap junction deficient bone. PLoS One 2011, 6:e23516.
17. Theis M., Mas C., Doring B., Kruger O., Herrera P., Meda P., et al. General and conditional replacement of connexin43-coding DNA by a lacZ reporter gene for cell-autonomous analysis of expression. Cell Commun Adhes 2001, 8:383-386.
18. Dacquin R., Starbuck M., Schinke T., Karsenty G. Mouse alpha1(I)-collagen promoter is the best known promoter to drive efficient Cre recombinase expression in osteoblast. Dev Dyn 2002, 224:245-251.
19. Truett G.E., Heeger P., Mynatt R.L., Truett A.A., Walker J.A., Warman M.L. Preparation of PCR-quality mouse genomic DNA with hot sodium hydroxide and tris (HotSHOT). Biotechniques 2000, 29:52-54.
20. Fang L.C., Cheng S.L., Mbalaviele G., Donsante C., Watkins M., Radice G.L., et al. Accentuated ovariectomy induced bone loss and altered osteogenesis in hyeterozygous N-cadherin null mice. J Bone Miner Res 2006, 21:1897-1906.
21. Geoffroy V., Paschalis E.P., Libouban H., Blouin S., Ostertag A., Chappard D., et al. Effects of risedronate in Runx2 overexpressing mice, an animal model for evaluation of treatment effects on bone quality and fractures. Calcif Tissue Int 2011, 88:464-475.
22. Fuchs R.K., Phipps R.J., Burr D.B. Recovery of trabecular and cortical bone turnover after discontinuation of risedronate and alendronate therapy in ovariectomized rats. J Bone Miner Res 2008, 23:1689-1697.
23. Allen M.R., Iwata K., Phipps R., Burr D.B. Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone 2006, 39:872-879.
24. Castro C.H., Shin C.S., Stains J.P., Cheng S.L., Sheikh S., Mbalaviele G., et al. Targeted expression of a dominant-negative N-cadherin in vivo delays peak bone mass and increases adipogenesis. J Cell Sci 2004, 117:2853-2864.
25. Willinghamm M.D., Brodt M.D., Lee K.L., Stephens A.L., Ye J., Silva M.J. Age-related changes in bone structure and strength in female and male BALB/c mice. Calcif Tissue Int 2010, 86:470-483.
26. Morgan E.F., Bouxsein M. Biomechanics of bone and age-related fractures. Principles of bone biology 2008, 29-51. Academic Press, San Diego, CA. 3rd ed. J.P. Bilezikian, L.G. Raisz, T.J. Martin (Eds.).
27. Aitchison K.J., Gonzalez F.J., Quattrochi L.C., Sapone A., Zhao J.H., Zaher H., et al. Identification of novel polymorphisms in the 5' flanking region of CYP1A2, characterization of interethnic variability, and investigation of their functional significance. Pharmacogenetics 2000, 10:695-704.
28. Fonseca H., Moreira-Goncalves D., Vaz M., Fernandes M.H., Ferreira R., Amado F., et al. Changes in proximal femur bone properties following ovariectomy and their association with resistance to fracture. J Bone Miner Metab 2012, 30:281-292.
29. Kousteni S., Chen J.R., Bellido T., Han L., Ali A.A., O'Brien C.A., et al. Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science 2002, 298:843-846.
30. Fonseca D., Ward W.E. Daidzein together with high calcium preserve bone mass and biomechanical strength at multiple sites in ovariectomized mice. Bone 2004, 35:489-497.
31. Li C.Y., Schaffler M.B., Wolde-Semait H.T., Hernandez C.J., Jepsen K.J. Genetic background influences cortical bone response to ovariectomy. J Bone Miner Res 2005, 20:2150-2158.
32. Chappard D., Retailleau-Gaborit N., Legrand E., Basle M.F., Audran M. Comparison insight bone measurements by histomorphometry and microCT. J Bone Miner Res 2005, 20:1177-1184.
33. Muller R., Van Campenhout H., Van Damme B., Van Der Perre G., Dequeker J., Hildebrand T., et al. Morphometric analysis of human bone biopsies: a quantitative structural comparison of histological sections and micro-computed tomography. Bone 1998, 23:59-66.
34. Tatsumi S., Ishii K., Amizuka N., Li M., Kobayashi T., Kohno K., et al. Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab 2007, 5:464-475.
35. Dobrowolski R., Hertig G., Lechner H., Worsdorfer P., Wulf V., Dicke N., et al. Loss of connexin43-mediated gap junctional coupling in the mesenchyme of limb buds leads to altered expression of morphogens in mice. Hum Mol Genet 2009, 18:2899-2911.
36. Paznekas W.A., Karczeski B., Vermeer S., Lowry R.B., Delatycki M., Laurence F., et al. GJA1 mutations, variants, and connexin 43 dysfunction as it relates to the oculodentodigital dysplasia phenotype. Hum Mutat 2009, 30:724-733.
37. Decrock E., Vinken M., De Vuyst E., Krysko D.V., D'Herde K., Vanhaecke T., et al. Connexin-related signaling in cell death: to live or let die?. Cell Death Differ 2009, 16:524-536.